Diabetes DPG Public Library

A randomized, double-blind, placebo-controlled pilot study investigated ubiquinol's impact on prediabetic patients' metabolic profiles. Findings indicated that ubiquinol supplementation significantly improved insulin sensitivity, as measured by reduced HOMA-IR values, in patients with impaired glucose tolerance. Ubiquinol also increased antioxidant enzyme activity, specifically catalase and glutathione peroxidase, and reduced markers of systemic inflammation like C-reactive protein. Additionally, research suggests ubiquinol may help maintain HDL-cholesterol and decrease LDL-cholesterol oxidation susceptibility, potentially reducing cardiovascular risk. The study suggests ubiquinol at 100–200 mg/day is well-tolerated and may slow prediabetes progression by improving insulin sensitivity and reducing oxidative stress.

Palakornkitti, Pasita, et al. Effects of Ubiquinol on Metabolic Profile in Prediabetic Patients: A Randomized, Double-blinded, Placebo-controlled Pilot Study. Clinical Nutrition Open Science (2026): 100627.